Nonliposomal Approach—A Study of Preparation of Egg Albumin Nanospheres Containing Amphotericin-B

Santhi, K; Dhanaraj, S. A.; Selvakumar, R.; Raja, K.; Ponnusankar, Sivasankaran; Suresh, B.

doi:10.1081/ddc-100102207

Cited by 9 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These preparations have been shown to be less toxic than AmB and to display altered pharmacokinetic properties because they are concentrated in the organs of the reticulo‐endothelial system, but not in the kidney where only low concentrations are achieved [5]. In addition to the incorporation in liposomes, AmB has also been incorporated in other drug delivery systems of smaller diameters than liposomes, namely egg albumin nanospheres [7], poly (ε‐caprolacton) or ethylcyanoacrylate nanoparticles [8, 9] or nanospheres [10] that are composed of soybean oil and egg yolk lecithin. These nanosphere preparations have been tested in vitro against strains of aspergillus [10], Cryptococcus neoformans [11] and in animal models of pulmonary aspergillosis [10], but there are no data on the therapeutic value of such preparations in systemic infection models with C. albicans .…”

Section: Introductionmentioning

confidence: 99%

Efficient treatment of murine systemic infection with Candida albicans using amphotericin B incorporated in nanosize range particles (emulsomes)

Kretschmar

Amselem

Zawoznik

et al. 2001

Mycoses

View full text Add to dashboard Cite

Summary. The effects of emulsome nanosize range lipid particles containing amphotericin B (EAmB) were compared with the reference formulation containing deoxycholate (Fungizone; Bristol‐Myers Squibb, Munich, Germany) and with the commercial amphotericin lipid complex preparation (AmBisome; Nexstar, San Dimas, CA, USA). The minimal inhibitory concentrations of Fungizone and EAmB were identical although killing of Candida albicans was delayed when EAmB was used. In a tissue culture model and in mice, the incorporation of AmB into emulsomes resulted in a considerable reduction of toxicity in comparison with Fungizone. For comparison of the in vivo effect of the preparations a mouse model of systemic infection with C. albicans was used. All preparations were able to reduce the fungal burden in the liver and kidneys in comparison with control animals treated with isotonic saline. AmBisome was more efficient in the reduction of the fungal burden of the liver than EAmB and Fungizone, even when applied in a similar dosage of 1 mg kg−1. In the kidneys, EAmB and Fungizone was slightly more effective than AmBisome. Therefore, in our models, the incorporation of AmB into nanosize particles was able to reduce toxicity without loss of efficiency. EAmB may be considered a candidate preparation for the treatment of infections with C. albicans in humans.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficient treatment of murine systemic infection with Candida albicans using amphotericin B incorporated in nanosize range particles (emulsomes)

Kretschmar

Amselem

Zawoznik

et al. 2001

Mycoses

View full text Add to dashboard Cite

show abstract

“…Albumin is a biocompatible and biodegradable carrier (35). The composition of the formulation and manufacturing procedures make feasible the production of a stable final product that could be an economically interesting alternative to the recently marketed lipid AMB formulations.…”

mentioning

confidence: 99%

Treatment of Experimental Visceral Leishmaniasis with Amphotericin B in Stable Albumin Microspheres

Sánchez‐Brunete¹,

Dea²,

Rama³

et al. 2004

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Hydrophilic albumin microspheres are proposed as a new delivery system for amphotericin B (AMB; AMB microspheres). The acute toxicity of AMB microspheres was lower than that of the AMB-deoxycholate (AMBDoc) reference formulation in hamsters. Lethal doses in healthy and infected animals were improved at least eight times. Intravenous bolus administration of doses of AMB microspheres up to 40 mg/kg of body weight did not produce acute symptoms of toxicity. The efficacy of this new formulation was tested against Leishmania infantum-infected hamsters at doses of 2, 10, 20, and 40 mg/kg. With the 2-mg/kg dose, the activity of AMB, as assessed through the parasite load reductions in the liver and spleen and the evolution of antibody levels, was also improved (P < 0.05) by use of the AMB microsphere system. At the higher doses of 10, 20, and 40 mg/kg, reductions in parasite levels of more than 99% were achieved in the liver and spleen after the administration of AMB microspheres. A pharmacokinetic study was performed to study the serum, liver, and spleen AMB concentrations after administration of AMB microspheres and the reference formulation. Interestingly, a significant accumulation of AMB in the spleen and liver was observed after AMB microsphere administration. Our results suggest that this new formulation is a promising alternative to the conventional AMB-Doc formulation for the treatment of visceral leishmaniasis.

show abstract

Chemotherapy of Leishmaniasis: A Veterinary Perspective

Corral‐Caridad

Alunda

2013

Trypanosomatid Diseases

View full text Add to dashboard Cite

Nonliposomal Approach—A Study of Preparation of Egg Albumin Nanospheres Containing Amphotericin-B

Cited by 9 publications

References 6 publications

Efficient treatment of murine systemic infection with Candida albicans using amphotericin B incorporated in nanosize range particles (emulsomes)

Efficient treatment of murine systemic infection with Candida albicans using amphotericin B incorporated in nanosize range particles (emulsomes)

Treatment of Experimental Visceral Leishmaniasis with Amphotericin B in Stable Albumin Microspheres

Chemotherapy of Leishmaniasis: A Veterinary Perspective

Contact Info

Product

Resources

About